INDIANAPOLIS, Sept. 21, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics for disorders associated with the human microbiome, today reported its participation in recent HBV scientific meetings in Asia.
Earlier today, Assembly's Qi Huang, PhD, presented preclinical data on the company's Core Protein Allosteric Modifiers (CpAMs) at the 2016 International HBV Meeting in Seoul, South Korea, in an oral session co-chaired by Assembly scientific co-founder Dr. Adam Zlotnick. Assembly's CpAMs are direct acting oral compounds that allosterically modulate HBV core protein, an essential viral protein involved in multiple critical functions throughout the HBV lifecycle.
Assembly researchers also participated in the 2nd Nanjing International Symposium on Oncogenic Viruses & Drug Discovery and Development held in Nanjing, China, September 16-18, 2016. In addition, Assembly's Chief Scientific Officer, Richard Colonno, PhD, gave a presentation on the company's HBV program at Nanfang Hospital in Guangzhou, China, Nanfang Hospital is an affiliate of Southern
Medical University, one of the premier academic medical institutions in China.
About Assembly Biosciences
Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV-cure program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biological therapeutics addressing diseases associated with the human microbiome. Assembly's HBV-cure program aims to increase the current low cure rates for chronic HBV. The company's highly experienced HBV team has collectively brought more than 10 anti-infective products to the market. They are pursuing several drug
candidates that inhibit multiple viral targets throughout the HBV lifecycle for possible use alone or in combination therapy. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICELTM, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, ABI-M101, is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates. For more information, visit assemblybio.com.
Assembly Biosciences, Inc.
Source: Assembly Biosciences
News Provided by Acquire Media